Breaking News, Collaborations & Alliances

Cellectis and Lonza Enter cGMP Manufacturing Service Agreement

Agreement covers manufacturing of clinical supply for Cellectis’ UCART pipeline

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on allogeneic gene-edited CAR T-cells (UCART), and Lonza have entered into a manufacturing service agreement covering clinical manufacturing of Cellectis’ allogeneic UCART product candidates targeting hematological malignancies. Lonza is in charge of implementing Cellectis’ manufacturing processes as per current Good Manufacturing Practices (cGMP) in a way that meets the highest quality and safety s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters